HDAX THERAPEUTICS ANNOUNCES APPOINTMENT OF DRS. ROMAN FLECK AND NEAL I. MUNI TO BOARD OF DIRECTORS

Appointment of veteran industry executives adds broad experience to HDAX team.

MISSISSAUGA, ON, April 11, 2023 /PRNewswire/ -- HDAX Therapeutics, Inc., ("HDAX"), a privately-held pharmaceutical company developing therapeutics for neurological and cardiac diseases stemming from microtubule dysfunction, today announced the appointment of Roman Fleck, Ph.D. as Executive Chairman of the Board and Neal I. Muni, M.D., MSPH, as an independent Board member.